Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
72.1M
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
38.7M
-
Shares change
-
+134K
-
Total reported value, excl. options
-
$99.8M
-
Value change
-
+$650K
-
Put/Call ratio
-
0.02
-
Number of buys
-
26
-
Number of sells
-
-21
-
Price
-
$2.58
Significant Holders of Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID) as of Q1 2023
69 filings reported holding OVID - Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share as of Q1 2023.
Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.7M shares
of 72.1M outstanding shares and own 53.7% of the company stock.
Largest 10 shareholders include Rubric Capital Management LP (7M shares), BVF INC/IL (6.85M shares), EcoR1 Capital, LLC (6.12M shares), Madison Avenue Partners, LP (3.1M shares), VANGUARD GROUP INC (2.61M shares), Artal Group S.A. (2.5M shares), ACADIAN ASSET MANAGEMENT LLC (1.78M shares), TLS Advisors LLC (1.38M shares), DRIEHAUS CAPITAL MANAGEMENT LLC (1.26M shares), and CHI Advisors LLC (865K shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.